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ROLE OF SELECT GENETIC VARIANTS IN LUNG CANCER RISK IN 
AFRICAN AMERICANS
The disparities between African Americans and whites in lung cancer incidence and 
mortality prompted efforts to further understand the underlying biological differences. 
Spitz and colleagues have previously shown that African Americans with prior emphysema 
have higher risks of lung cancer compared with white lung cancer patients. The present 
study, therefore, included a panel of 1440 inflammatory gene variants in a two-phase analy-
sis (discovery and replication), top Genome-Wide Association Studies (GWAS) hits from 
lung cancer in whites, and 28 single nucleotide polymorphisms (SNPs) from a published 
gene panel. This study would also evaluate the addition of select genetic hits in improving 
their risk prediction models for African Americans. The findings revealed 154 significant 
SNPs in inflammation, and one in REV1 (suggested role in translesion synthesis), and three 
GWAS hits (2 in the 15q locus and 1 in the HTERT locus) in the discovery set, and one 
replicated inflammation SNP between IRF4 and EXOC2. This study has demonstrated that 
incorporating these SNPs into risk-prediction models did not improve the model perfor-
mance substantially or present any clinical relevance for African American lung cancer 
cases. The analysis suggested the role of inflammation pathway, smoking-related genes, 
and TERT and Rev1 in lung cancer development in African Americans.
Spitz MR, Amos CI, Land S, et al. Role of Selected Genetic Variants in Lung Cancer Risk in 
African Americans. J Thoracic Oncol 2013;8:391-397.
PATTERNS OF DNA MUTATIONS AND ALK REARRANGEMENT IN 
RESECTED NODE-NEGATIVE LUNG ADENOCARCINOMA
The genetic mutation profiles of patients with resected lung adenocarcinoma have 
been extensively assessed, primarily in the advanced or metastatic stage. However, infor-
mation on the mutation status of patients at early-stage node-negative disease is limited. 
Yip and colleagues, therefore, conducted a study to examine the patterns of mutations in 
these diseases. Mutation analysis and fluorescence in situ hybridization were performed 
on tumors from 204 patients, with resected stage IB lung adenocarcinoma and without 
neoadjuvant or adjuvant treatments. The study revealed diverse patterns of mutations in 
these tumors, including KRAS, EGFR, PIK3CA, ALK, PDGFRA, AKT1, BRAF, FGFR1, 
and HRAS, with at least one of these mutations in a little more than half of the patients. 
In these early-stage tumors, a high rate (8.8%) of synchronous mutations, either comuta-
tions or double mutations, was detected, whereas only 1% harbored an ALK rearrangement. 
Correlation of mutation status to disease prognosis was established: KRAS and PIK3CA 
mutations are linked to poorly differentiated tumors, whereas EGFR mutations are linked 
to well-differentiated tumors. EGFR mutations associated with resistance to epidermal 
growth factor receptor (EGFR) tyrosine kinase inhibitors were also found in 2.5% of the 
tumors. These findings are useful in providing information about future adjuvant-targeted 
therapy trials where specific mutations may affect the response to therapy.
Yip PY, Yu B, Cooper WA, et al. Patterns of DNA Mutations and ALK Rearrangement in Resected 
Node Negative Lung Adenocarcinoma. J Thoracic Oncol 2013;8:408-414.
THE PROGNOSTIC VALUE OF RATIO–BASED LYMPH-NODE STAGING 
IN RESECTED NON–SMALL-CELL LUNG CANCER
For patients with non–small-cell lung cancer (NSCLC), lymph-node (LN) staging 
is currently the strongest prognostic indicator. LN staging for NSCLC in the current 
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tumor, node, metastasis classification is based on the anatomical location of involved LNs, 
although there is growing evidence establishing the number of metastatic LNs (MLNs) and 
lymph-node ratio ([LNR], ratio of positive LNs divided by total number of retrieved LNs) 
as prognostic indicators. This retrospective study aimed to assess the LNR staging for the 
prognosis of patient with resected NSCLC and to compare its prognostic significance with 
the MLN staging, and the traditional pN staging. Apart from MLN and LNR, a number of 
potential factors (age, sex, smoking status, location of tumor, histology, pathology T stage, 
pN stage, surgical procedure, and chemotherapy) were also evaluated for prognostic value 
on survival of the 480 NSCLC patients undergoing radical resection between 2006 and 
2008. The findings show an association of higher LNR with worse overall survival and 
disease-free survival in the whole series, and no difference in N2 patients. LNR, smoking 
status, and chemotherapy are determined as independent predictors for overall survival 
and disease-free survival in NSCLC patients undergoing radical surgery. LNR, though not 
proven to be superior to pN staging in this study, would provide more informative prognosis 
when combined with pN status (N1 patients in this case).
Qiu C, Dong W, Su B, et al. The Prognostic Value of Ratio-Based Lymph Node Staging in Resected 
Non-Small-Cell Lung Cancer. J Thoracic Oncol 2013;8:429-435.
Research Watch
EML4-ALK–POSITIVE NSCLC PATIENT DEVELOPED SEVERE ACUTE 
INTERSTITIAL LUNG DISEASE AFTER CRIzOTINIB TREATMENT
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors–associated inter-
stitial lung disease (ILD) has been identified previously. Tamiya and colleagues reported here 
the first case of crizotinib-associated ILD in an EML4-ALK–positive non–small-cell lung 
cancer patient. Crizotinib (Xalkori, Pfizer) is generally well-tolerated with pronounced clini-
cal activity, but clinicians should be aware of the possibility of this severe adverse reaction. 
Because of the high mortality resulting from drug-induced ILD, it is important to determine 
the prevalence and risk factors of crizotinib-associated ILD.
Tamiya A, Okamoto I, Miyazaki M, et al. Severe Acute Interstitial Lung Disease after 
Crizotinib Therapy in a Patient with EML4-ALK-Positive Non-Small-Cell Lung Cancer. J Clin Oncol 
2013;31:e15-e17.
GEFITINIB-INDUCED GASTRIC PERFORATION IN METASTATIC  
LUNG CANCER
This was the first reported case of gefitinib-induced gastric perforation for metastatic 
lung cancer because of tumor necrosis after treatment. Epidermal growth factor receptor 
(EGFR) tyrosine kinase inhibitors–sensitive mutation (exon 19 deletion) was found in both 
the primary tumor of lung origin and at the metastatic site. This severe complication should 
be monitored when treating patients with drug-sensitive EGFR mutations, with the use of 
imaging to detect possible gastrointestinal changes.
Chung WP, Song HL, Ho C L, Chiu NT, Su WC. Gastric perforation secondary to regression 
of lung adenocarcinoma after gefitinib treatment. J Clin Oncol 2013;31:e6–e8.
NONINVASIVE [11C]ERLOTINIB POSITRON EMISSION TOMOGRAPHY 
FOR ASSESSMENT OF EGFR MUTATION
Bahce and colleagues assessed whether quantification and imaging of tumor uptake 
of [11C]erlotinib in patients with non–small-cell lung cancer (NSCLC) using positron emis-
sion tomography was possible. They also determined whether the level of tracer uptake 
corresponded with the presence of activating tumor EGFR mutations. The quantitative 
387Copyright © 2013 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology  •  Volume 8, Number 4, April 2013 
measure of [11C]erlotinib uptake (i.e., volume of distribution) was found to be significantly 
higher in NSCLC tumors with EGFR exon 19 deletions, than in those without activating 
EGFR mutations. This finding supports the use of noninvasive [11C]erlotinib positron emis-
sion tomography in identifying NSCLC patients who could benefit from tyrosine kinase 
inhibitor treatment.
Bahce I, Smit EF, Lubberink M, et al. Development of [11C]erlotinib Positron Emission 
Tomography for In Vivo Evaluation of EGF Receptor Mutational Status. Clin Cancer Res 
2013;19:183-193.
NEXT-GENERATION SEQUENCING DETECTS EGFR MUTATION IN 
BRONCHOALVEOLAR LAVAGE AND PLEURAL FLUIDS
Compared with Sanger sequencing, this sensitive EGFR next-generation sequencing 
assay can detect mutation in these biological samples with low number of tumor cells, but 
large number of normal cells and inflammatory elements. The finding would extend the epi-
dermal growth factor receptor (EGFR) testing to patients with limited amount of materials 
for molecular diagnosis. Therefore, specific therapies will be available for these patients, 
who otherwise would be directed to rebiopsies or nontargeted treatments.
Buttitta F, Felicioni L, Del Grammastro M, et al. Effective Assessment of EGFR Mutation 
Status in Bronchoalveolar Lavage and Pleural Fluids by Next-Generation Sequencing. Clin Cancer 
Res 2013; doi: 10.1158/1078-0432.ccr-12-1958.
News in Brief
PRESIDENT OBAMA SIGNED THE RECALCITRANT CANCER  
RESEARCH ACT INTO LAw
The bill (originally known as the Pancreatic Cancer Research and Education Act) 
mandates that the National Cancer Institute prioritize efforts in pancreatic cancer, lung can-
cer, and other recalcitrant cancers (5-year survival rate <50%), and make comprehensive 
scientific plans to improve outcomes.
LUNG CANCER MORTALITY ON THE GLOBAL AND NATIONAL SCALE
On the basis of the Global Burden of Diseases, Injuries, and Risk Factors Study 
2010, topping the global ranking of cancer mortality, deaths from trachea, bronchus, 
and lung cancers increased dramatically (by 48%; eighth to fifth on causes of death 
ranking worldwide). Other increases include liver cancer (by 63%; 24th to 16th), and 
colorectal cancer (by 46%; 21st to 19th). However, overall U.S. cancer death rates 
dropped by 1.8% per year for men, 1.4% for women, and 1.8% for children from 2000 
to 2009, according to the 2013 Annual Report to the nation on the status of cancer. 
The report also showed increased incidence rates for certain human papillomavirus–
related cancers.
ESOPHAGEAL CANCER SCREENING: RAPID AND DETAILED IMAGING 
FROM A PILL-SIzED DEVICE
Researchers at the Wellman Center for Photomedicine at Massachusetts General 
Hospital have developed a novel imaging system encapsulated in a pill-sized device to 
screen for Barrett’s esophagus, a precancerous condition. After being swallowed down the 
esophagus, it provides three-dimensional images of microscopic structures of the esopha-
gus lining from a small capsule attached to a flexible tether. Compared with conventional 
endoscopy, additional advantages of using the new device are short procedure (approxi-
mately 6 minutes) and no sedation, trained personnel, special equipment, and setting are 
required. This inexpensive and low-risk device would allow broader screening and potential 
prevention of esophagus cancer.
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AMERICAN CANCER SOCIETY UPDATED GUIDELINES ON LUNG 
CANCER SCREENING
The American Cancer Society (ACS) released these guidelines, concluding sufficient 
evidence supporting annual lung cancer screening, using low-dose computed tomography 
in specific high-risk groups: 55- to 74–year-olds with a history of smoking. The guidelines 
also include ACS acknowledgment of concerns such as relatively high level of false-posi-
tive findings, and ACS outline of recommendations to clinicians in identification of patients 
for screening, and discussion about different aspects of screening with them.
BOEHRINGER INGELHEIM’S AFATINIB NDA ACCEPTED BY U.S. FDA 
wITH PRIORITY REVIEw STATUS
Afatinib is under review for the treatment of patients with locally advanced or 
metastatic non–small-cell lung cancer with an EGFR mutation. The Food and Drug 
Administration target action date for afatinib will be in the third quarter of 2013. Afatinib 
has demonstrated superiority compared with the best–in-class chemotherapy (pemetrexed/
cisplatin), with 11.1 months progression-free survival versus 6.9 months in the comparator 
arm. Patients treated with afatinib also showed better management of disease-related symp-
toms and better overall quality of life. Adverse events were expected with EGFR inhibi-
tors, and were manageable, and reversible. Afatinib was also submitted to the European 
Medicines Agency for Marketing Authorisation review in 2012.
